论文部分内容阅读
目的:探讨血府逐瘀汤联合甲钴铵治疗糖尿病末梢神经病变的疗效,为血府逐瘀汤联合甲钴铵治疗糖尿病末梢神经病变的临床应用提供理论依据。方法:选取2013年2月-2015年2月在医院接受治疗的90例糖尿病末梢神经病变患者作为此次研究对象,分为观察组与对照组,每组45例,对照组患者单纯采用甲钴胺片进行治疗,观察组在对照组的基础上联合血府逐瘀汤进行治疗,分析两组患者治疗前后运动传导速度(MNCV)变化情况,分析两组患者治疗前后感觉传导速度(SNCV)变化情况,分析两组患者治疗效果情况。结果:治疗前,两组患者MNCV和SNCV变化差异不明显,无统计学意义(P>0.05);治疗后,观察组MNCV和SNCV变化明显高于对照组,两组之间差异显著,具有统计学意义(P<0.05);观察组总有效率为86.67%,对照组为64.44%,观察组明显高于对照组,两组之间差异显著,具有统计学意义(P<0.05)。结论:血府逐瘀汤联合甲钴铵治疗糖尿病末梢神经病变疗效显著,改善了患者MNCV和SNCV情况,提高了治疗效果。
Objective: To investigate the efficacy of Xuefu Zhuyu Decoction combined with mecobalamin in the treatment of diabetic peripheral neuropathy, and to provide a theoretical basis for the clinical application of Xuefu Zhuyu Decoction combined with mecobalamin in the treatment of diabetic peripheral neuropathy. Methods: Totally 90 patients with diabetic peripheral neuropathy treated in the hospital from February 2013 to February 2015 were selected as observation group and control group, with 45 cases in each group. Patients in the control group were treated with mecobalamin The observation group was treated with Xuefu Zhuyu Decoction on the basis of the control group. The changes of motor conduction velocity (MNCV) before and after treatment in both groups were analyzed. The changes of sensory conduction velocity (SNCV) before and after treatment were analyzed , Analysis of two groups of patients treatment effect. Results: Before treatment, there was no significant difference in MNCV and SNCV between the two groups (P> 0.05). After treatment, the changes of MNCV and SNCV in the observation group were significantly higher than those in the control group, with significant difference between the two groups (P <0.05). The total effective rate was 86.67% in the observation group and 64.44% in the control group. The observation group was significantly higher than the control group, with significant difference between the two groups (P <0.05). Conclusion: Xuefu Zhuyu Decoction combined with methylcobalamin treatment of diabetic peripheral neuropathy significant effect, improve the MNCV and SNCV patients, and improve the therapeutic effect.